Cizzle Bio Announces Laboratory Validation of CIZ1B Biomarker Blood Test for Early Lung Cancer at OmniHealth Diagnostics
DALLAS, June 16, 2026 /PRNewswire/ -- Cizzle Bio, Inc., a Texas-based biotechnology company advancing biomarker blood tests for early detection of lung and gastric cancers, today announced the laboratory validation of its proprietary CIZ1B biomarker blood test for early lung cancer at...
DALLAS, June 16, 2026 /PRNewswire/ -- Cizzle Bio, Inc., a Texas-based biotechnology company advancing biomarker blood tests for early detection of lung and gastric cancers, today announced the laboratory validation of its proprietary CIZ1B biomarker blood test for early lung cancer at...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.